share_log

Reneo Pharmaceuticals Receives Fast Track Designation From FDA For Mavodelpar In A Genotype Af Long-Chain Fatty Acid Oxidation Disorder

Reneo Pharmaceuticals Receives Fast Track Designation From FDA For Mavodelpar In A Genotype Af Long-Chain Fatty Acid Oxidation Disorder

Reneo Pharmicals因Mavodelpar在基因型Af长链脂肪酸氧化障碍中获得美国食品药品管理局的快速通道认证
Benzinga Real-time News ·  2023/01/31 07:42

Reneo Pharmaceuticals Receives Fast Track Designation From FDA For Mavodelpar In A Genotype Af Long-Chain Fatty Acid Oxidation Disorder

Reneo Pharmicals因Mavodelpar在基因型Af长链脂肪酸氧化障碍中获得美国食品药品管理局的快速通道认证

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发